Blockchain Registration Transaction Record

NanoViricides' NV-387 Eyed for Ebola Outbreak Response

NanoViricides proposes NV-387 for Bundibugyo Ebola strain with no approved treatments. Oral formulation and Phase II trial for mpox may accelerate availability. Learn more about NNVC.

This news is important because the Bundibugyo strain Ebola outbreak in Africa lacks approved vaccines or therapies, creating a critical gap in pandemic preparedness. NanoViricides' NV-387, with its host-targeted mechanism and oral formulation, could offer a rapidly deployable treatment option that enhances healthcare worker safety and accessibility in remote areas. If successful, it would mark a significant advancement in antiviral therapy, potentially addressing multiple viral threats including mpox and COVID-19, and strengthening global health security against emerging infectious diseases.